Editorial
doi: 10.1002/jbmr.4022.
Epub 2020 Apr 21.
Zoledronate Following Denosumab Discontinuation: Partial Reassurance but No Confidence
Affiliations
- PMID: 32315077
- DOI: 10.1002/jbmr.4022
Item in Clipboard
Editorial
Zoledronate Following Denosumab Discontinuation: Partial Reassurance but No Confidence
J Bone Miner Res.
2020 Jul.
Free article
No abstract available
Comment on
-
A Single Infusion of Zoledronate in Postmenopausal Women Following Denosumab Discontinuation Results in Partial Conservation of Bone Mass Gains.J Bone Miner Res. 2020 Jul;35(7):1207-1215. doi: 10.1002/jbmr.3962. Epub 2020 Feb 11. J Bone Miner Res. 2020. PMID: 31991007
Similar articles
-
Circulating sclerostin levels during denosumab discontinuation and the subsequent early or late zoledronate infusion.Endocrine. 2021 Jul;73(1):223-225. doi: 10.1007/s12020-021-02666-5. Epub 2021 Mar 2. Endocrine. 2021. PMID: 33651343 No abstract available.
-
Bone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates.Calcif Tissue Int. 2018 Jul;103(1):55-61. doi: 10.1007/s00223-018-0404-6. Epub 2018 Feb 14. Calcif Tissue Int. 2018. PMID: 29445836
-
Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.Metabolism. 2015 Oct;64(10):1291-7. doi: 10.1016/j.metabol.2015.06.018. Epub 2015 Jun 27. Metabolism. 2015. PMID: 26198440 Clinical Trial.
-
Antiresorptive agents' bone-protective and adjuvant effects in postmenopausal women with early breast cancer.Br J Clin Pharmacol. 2019 Jun;85(6):1125-1135. doi: 10.1111/bcp.13834. Epub 2019 Jan 25. Br J Clin Pharmacol. 2019. PMID: 30536446 Free PMC article. Review.
-
[Inhibition of RANK ligand to treat bone metastases].Bull Cancer. 2013 Nov;100(11):1207-13. doi: 10.1684/bdc.2013.1835. Bull Cancer. 2013. PMID: 24158618 Review. French.
Cited by
-
A Multi-Institutional Randomized Controlled Trial to Investigate Whether Zoledronate Prevents Bone Loss After Discontinuation of Denosumab: The Study Protocol of Denosumab Sequential Therapy (DST) Trial.Front Med (Lausanne). 2021 Sep 8;8:717168. doi: 10.3389/fmed.2021.717168. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34568375 Free PMC article.
-
Safety of therapy with and withdrawal from denosumab in fibrous dysplasia and McCune-Albright syndrome: an observational study.J Bone Miner Res. 2021 Sep;36(9):1729-1738. doi: 10.1002/jbmr.4380. Epub 2021 Jun 10. J Bone Miner Res. 2021. PMID: 34076303 Free PMC article.
References
-
- Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5(7):513-23.
-
- Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab. 2011;96(4):972-80.
-
- Boonen S, Ferrari S, Miller PD, et al. Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk-a perspective. J Bone Miner Res. 2012;27(5):963-74.
-
- Tripto-Shkolnik L, Fund N, Rouach V, Chodick G, Shalev V, Goldshtein I. Fracture incidence after denosumab discontinuation: real-world data from a large healthcare provider. Bone. 2020;130:115150.
-
- Cummings SR, Ferrari S, Eastell R, et al. Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res. 2018;33(2):190-8.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
